Jinfeng Luo

Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib

Xiaomei Ren, Xiaofen Pan, Zhang Zhang et al. · Journal of Medicinal Chemistry · 2013 · 174 citations · Full text

Discovery and Optimization of 3-(2-(Pyrazolo[1,5-<i>a</i>]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors

Mingshan Gao, Lei Duan, Jinfeng Luo et al. · Journal of Medicinal Chemistry · 2013 · 154 citations · Full text

Drug Target, Chemoprevention Strategy, Pharmacotherapy +19

Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine⁷⁹⁰ → Methionine⁷⁹⁰ Mutant

Shaohua Chang, Lianwen Zhang, Shilin Xu et al. · Journal of Medicinal Chemistry · 2012 · 83 citations · Full text

Drug Target, Engineering, Molecular Biology +20

Spiro Meroterpenoids from <i>Ganoderma applanatum</i>

Qi Luo, Xiaoyi Wei, Jing Yang et al. · Journal of Natural Products · 2016 · 77 citations · Full text

EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer

Yang Li, Yanhong Duo, Shiyun Bao et al. · International Journal of Nanomedicine · 2017 · 68 citations · Full text